Insider buying last 90 days
No open-market insider purchases were filed for TVTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Travere Therapeutics closed at $51.63 on 9 November 2026, +4.1% on the day. The price sits between the 50-day ($57.12) and 200-day ($47.26) moving averages, inside a 52-week range of $22.59 to $68.73. The GekkoIndex reads 62.3, in the Accumulation zone, down 6.8 points over five sessions. Gekko Fair Value is $64.48, so the price is 19.9% below it.
The next earnings report is due on 18 February 2027, 95 days away (after close). Over the last 8 reports the company beat the earnings estimate 4 times, with an average move of 6.6% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +4.3% over the last 5 years, rising in 3 of them.
11 firms rate the stock: 10 buy, 1 hold and 0 sell, with a consensus target of $75.14. A typical daily move is about 5.3%, and a typical 20-day move about 11.1%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 9, 2026 close.
Travere Therapeutics scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $50.65 sits between the 50-day ($55.93) and 200-day ($47.68) averages, or the averages disagree.
See the chart60.5, Accumulation
Reading 60.5 is in the Accumulation zone.
See the GekkoIndex19.5% below
Price is 19.5% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earnings+4.1% on average
From this point in the calendar, the next 20 trading days averaged +4.1% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Travere Therapeutics closed at $50.65 on Nov 13, 2026, +38.9% over the past year, inside a 52-week range of $22.59 to $68.73.
Use the left and right arrow keys to read daily values.
Put TVTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Travere Therapeutics focuses on treatments for rare conditions affecting the kidneys and metabolism. Its best-known product is FILSPARI, an oral, once-daily medicine that works against two biological pathways linked to disease progression and has been approved to slow kidney decline in adults with primary IgA nephropathy at risk of worsening, and later cleared to reduce proteinuria in patients eight and older with focal segmental glomerulosclerosis without nephrotic syndrome, a condition for which it stands as the only approved medicine of its kind.
Beyond FILSPARI, the company sells Thiola and Thiola EC, tiopronin tablets used to treat cystinuria, a genetic disorder that causes repeated kidney stones. It is also developing pegtibatinase, an experimental enzyme replacement therapy aimed at classical homocystinuria, which remains in its pipeline rather than on the market. Its customers are patients and physicians treating these rare inherited and progressive diseases.
The company was previously known as Retrophin, Inc. before adopting the Travere name in November 2020. It is based in San Diego, California, and incorporated in Delaware. Travere Therapeutics is listed on the NASDAQ under the ticker TVTX.
Travere Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.5, in the Accumulation zone, down 5.8 points over five sessions.
Down 5.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | −0.7% | +14.3% | ||
| Accumulation (current zone) | 188 | +0.9% | +4.6% | ||
| Neutral | 426 | +1.9% | +7.4% | ||
| Distribution | 52 | +3.4% | +8.1% | ||
| Selling | 4 | Too few readings yet | |||
Average TVTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Travere Therapeutics trades 19.5% below Gekko Fair Value of $62.93, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Travere Therapeutics shares are worth, recalculated every trading day.
$62.93
Gekko Fair Value, Nov 14, 2026
19.5% Undervalued
At the end of Aug 2026 the price was 4.0% below the estimate.
No open-market insider purchases were filed for Travere Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for TVTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in TVTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Nov 6, $488K in unusual premium.
1of the funds Gekko tracks holds TVTX.
Travere Therapeutics reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 18, 2027
Expected after the close, 95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | −$0.55 est −$0.10 | $224.6M est $195.3M | −1.9% |
| Aug 4, 2026 | −$0.37 est −$0.14 | $169.6M est $157.3M | +14.2% |
| May 4, 2026 | $0.05 est −$0.06 | $127.2M est $136.2M | +1.5% |
| Feb 19, 2026 | $0.03 est $0.03 | $129.7M est $144.6M | +9.0% |
| Oct 30, 2025 | $0.28 est −$0.31 | $164.9M est $147.0M | +17.3% |
| Aug 6, 2025 | $0.13 est $0.04 | $114.4M est $99.55M | +1.4% |
| May 1, 2025 | −$0.19 est −$0.39 | $81.73M est $88.80M | +1.6% |
| Feb 20, 2025 | −$0.47 est −$0.38 | $74.79M est $72.38M | −5.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Travere Therapeutics is $73.43, +45.0% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 5 | Leerink Partners | $67 | +32.3% |
| Nov 4 | Canaccord Genuity | $72 | +42.2% |
| Nov 3 | Cantor Fitzgerald | — | — |
| Nov 3 | H.C. Wainwright | $67 | +32.3% |
| Nov 3 | Wells Fargo | $80 | +57.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Travere Therapeutics averaged +4.1% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.7% | 2 of 5 |
| Next 10 trading days | −1.5% | 3 of 5 |
| Next 15 trading days | +4.6% | 2 of 5 |
| Next 20 trading days | +4.1% | 2 of 5 |
| Next 30 trading days | +11.1% | 3 of 5 |
For scale, TVTX’s typical 20-trading-day move in either direction is about 11.1%.
Travere Therapeutics’s market cap is $4.86B and revenue of $651.0M over the last twelve months.
Coverage of Travere Therapeutics this week reads neutral: 1 positive, 3 neutral and 1 negative headlines.
Travere Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Travere Therapeutics’s market cap is $4.86B at the Nov 13, 2026 close of $50.65, with 95.99M shares outstanding.
The consensus analyst 12-month price target for Travere Therapeutics is $73.43, +45.0% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Travere Therapeutics is undervalued: the Nov 13, 2026 close of $50.65 is 19.5% below Gekko Fair Value of $62.93. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Travere Therapeutics is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of $0.44 per share on revenue of $247.5M. Travere Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 6.6% on average across the report.
Travere Therapeutics’s 52-week high is $68.73 and its 52-week low is $22.59; it closed at $50.65 on Nov 13, 2026, +38.9% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Travere Therapeutics over the last 30 days, with $488K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 6, 2026 with $488K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.